| __timestamp | Catalyst Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 5496000 |
| Thursday, January 1, 2015 | 8597010 | 9786000 |
| Friday, January 1, 2016 | 7910260 | 6792000 |
| Sunday, January 1, 2017 | 7304399 | 7313000 |
| Monday, January 1, 2018 | 15875961 | 8382000 |
| Tuesday, January 1, 2019 | 36881187 | 10803000 |
| Wednesday, January 1, 2020 | 44233754 | 12944000 |
| Friday, January 1, 2021 | 49628000 | 21967000 |
| Saturday, January 1, 2022 | 58183000 | 32810000 |
| Sunday, January 1, 2023 | 133710000 | 46542000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Catalyst Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses.
Catalyst Pharmaceuticals has seen a dramatic increase in SG&A expenses, skyrocketing by nearly 2,900% from 2014 to 2023. This surge reflects their aggressive market expansion and investment in administrative capabilities. By 2023, their SG&A expenses reached a peak, indicating a strategic push in their operational framework.
Conversely, Xenon Pharmaceuticals has maintained a more conservative growth in SG&A spending, with a 747% increase over the same period. This steady rise suggests a balanced approach, focusing on sustainable growth and efficient resource allocation.
These contrasting strategies highlight the diverse approaches within the pharmaceutical industry, offering insights into how companies prioritize their operational expenditures.
Operational Costs Compared: SG&A Analysis of AbbVie Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Walgreens Boots Alliance, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.